# NCI Clinical Trial Research Strategy, Harnessing of Equity, and Implementation

> **NIH NIH R50** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $173,920

## Abstract

PROJECT SUMMARY/ABSTRACT
I am a female board-certified radiation oncologist and Professor at the University of California (UC), San Diego,
in the Department of Radiation Medicine. My research and clinical efforts involve every phase of gynecologic
(GYN) clinical trials with a focus on translational science, and I am a leader in the NRG Oncology NCI network.
My national leadership within NRG Oncology spans over 13 years: I served as a core Member of the Radiation
Oncology GOG committee (2009–2015), the Phase I Developmental Therapeutics Committee, and the
Cervical Cancer Committee, which lead to service as Co-Chair of the GYN Developmental Therapeutics
Committee 2015–2018 and receipt of a National Service Award from NRG Oncology as the Co-Chair of the
Phase I Committee in 2018. I then transitioned to the NRG cervical cancer co-chair from 2018-present. In
these roles, I develop the strategic outline of advancing NCI clinical trials though writing, development of new
trials, accrual, and public dissemination of the results in a timely fashion. I am also keenly involved with the
mentorship of junior investigators at the NRG to increase underrepresented diversity as investigators on
national clinical trials and serve as the principal investigator, primary mentor, or study team on 13 proposals in
the GYN portfolio at NRG since 2018. At UCSD, I am heavily involved with the clinical trials office and have
grants through the UCSD community outreach and engagement to increase equity among NCI clinical trial
enrollment. I serve as the Co-Leader of the GYN Disease Team at the Moores Cancer Center (MCC), the
UCSD Co-PI for the ECTCN trial network on MCC’s UM1 ETCTN grant (VICKtOrY Early Clinical Trials
Consortium; UM1CA186689), with the goal of bringing lab discoveries to the treatment of patients and
improving accrual of underserved populations. I developed a pipeline of early phase clinical trials in node
positive high risk cervical cancer with NCI funding as principal investigator from 2009 for GOG 9292 “Phase I
trial using sequential ipilimumab in locally advanced cervical cancer.” and received a NCI career development
award for the clinical trial in 2018 as principal investigator on GYN NRG 017, “Anti PD-L1 (Atezolizumab) as an
immune primer and concurrently with extended field chemoradiotherapy for node positive locally advanced
cervical cancer.” My goal is to expand our current efforts to offer NCI-funded clinical trials throughout the
region, and ensure equity access to them through clinical trial development, expansion of our clinical trials
office in strategic areas of underrepresented minority accrual. With the R50 Award, I would (1) expand my
current efforts as a PI and mentor PI for novel clinical trial submissions in the NCI funded NRG Oncology
network for GYN patients nationally and locally; (2) ensure equity leadership as investigator status within NRG
Oncology clinical trials, and explore biomarker-driven clinical trial translational samples ...

## Key facts

- **NIH application ID:** 10721134
- **Project number:** 1R50CA282102-01
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Jyoti Mayadev
- **Activity code:** R50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $173,920
- **Award type:** 1
- **Project period:** 2023-09-04 → 2028-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10721134

## Citation

> US National Institutes of Health, RePORTER application 10721134, NCI Clinical Trial Research Strategy, Harnessing of Equity, and Implementation (1R50CA282102-01). Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/grant/nih/10721134. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*